Ozmosi | L-serine Drug Profile

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous, Subcutaneous, Oral

FDA Designation: *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: M.D. Anderson Cancer Center
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Other|Renal Transplant

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
ChiCTR2400089707	ChiCTR2400089707	N/A	Not yet recruiting	Kidney Diseases	2026-01-01
NCT06377631	FATHIS+	N/A	Completed	Liver Diseases, Alcoholic\|Non-alcoholic Fatty Liver Disease\|Fatty Liver, Alcoholic\|Obesity, Abdominal	2025-04-08	2025-04-18
ACTRN12619000561189	ACTRN12619000561189	N/A	Recruiting	Hereditary Sensory Neuropathy Type 1	2024-12-31	2024-08-29	Treatments
NCT05807204	FATHIS	N/A	Completed	Non-alcoholic Fatty Liver Disease\|Liver Diseases, Alcoholic\|Obesity, Abdominal\|Fatty Liver, Alcoholic	2023-12-20	2024-02-24
NCT04646447	PIC-29-20	N/A	Unknown status	Brain Diseases	2021-08-31	2022-11-03	Primary Endpoints\|Treatments\|Trial Status
NCT02528994	2014D001170	N/A	Withdrawn	Type 2 Diabetes\|Hypertension	2016-09-01	2019-03-20
NCT06626256	NCI-2024-08121	P1	Not yet recruiting	Pancreatic Ductal Carcinoma\|Colorectal Cancer\|Pancreatic Cancer\|Adenocarcinoma\|Renal Cell Carcinoma\|Cervical Cancer\|Uterine Cancer\|Melanoma	2027-10-30	2025-08-27	Primary Endpoints\|Start Date\|Treatments
NCT03240861	NYESO SCT	P1	Terminated	Sarcoma	2023-10-19	2023-11-02	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT02774291	NCI-2015-01781	P1	Terminated	Oncology Solid Tumor Unspecified\|Oncology Hematological Unspecified	2020-07-01	2023-08-05	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT01630564	NCI-2013-00385	P1	Terminated	Stem Cell Transplant\|Graft vs Host Disease	2018-05-30	2019-03-19	Treatments
NCT06113055	SENSE	P2	Unknown status	Hereditary Sensory and Autonomic Neuropathies	2025-08-01	2025-11-01	Primary Endpoints\|Treatments\|Trial Status
NCT03580616	ALS	P2	Terminated	Amyotrophic Lateral Sclerosis	2022-08-03	2023-05-10	Primary Endpoints\|Treatments
NCT01823198	NCI-2013-00993	P2	Completed	Myeloid, Accelerated Leukemia\|Acute Erythroblastic Leukemia\|Juvenile Myelomonocytic Leukemia,\|Blast Crisis\|Preleukemia\|Acute Monocytic Leukemia\|Acute Myelomonocytic Leukemia\|Acute Myeloid Leukemia\|Acute Megakaryoblastic Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Myelodysplastic Syndrome\|Chronic Myelomonocytic Leukemia\|Chronic Myeloid Leukemia	2022-05-10	2022-06-01	Primary Endpoints
NCT03062449	LSPI-2	P2	Terminated	Alzheimer Disease	2021-07-20	2024-07-05	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT02620865	NCI-2015-01942	P2	Completed	Adenocarcinoma\|Pancreatic Cancer	2021-06-21	2025-02-07
NCT02408016	NCI-2015-00329	P2	Terminated	Non-Small-Cell Lung Cancer\|Mesothelioma\|Pleural Cancer	2020-06-30	2022-04-06	Primary Endpoints\|Treatments
NCT02770820	NCI-2016-00042	P2	Terminated	Acute Myeloid Leukemia	2020-06-01	2022-04-06	Primary Endpoints
NCT01640301	NCI-2011-03362	P2	Terminated	Acute Myeloid Leukemia	2020-03-20	2022-06-24	Primary Endpoints
NCT01835782	L-Serine2013	P2	Unknown status	Amyotrophic Lateral Sclerosis	2016-12-01	2019-03-19	Treatments
NCT01758458	NCI-2012-02779	P2	Terminated	Carcinoma, Merkel Cell	2016-05-01	2022-04-06	Primary Endpoints\|Treatments
NCT01733407	FD-R-04127-01	P2	Completed	Peripheral Nervous System Diseases\|Hereditary Sensory and Autonomic Neuropathies	2016-05-01	2019-03-19	Treatments
2024-519757-11-00	RR-DVIVO	P3	Not yet recruiting	Renal Transplant	2027-12-31	2025-05-02	Treatments
2022-000241-32	2022-000241-32	P3	Completed	Other	2024-03-26	2025-05-06	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status

Recent News Events

Date	Type	Title
05/15/2024	PubMed	The truncated AXIN1 isoform promotes hepatocellular carcinoma metastasis through SRSF9-mediated exon 9 skipping.
05/15/2024	PubMed	Exploration of three Dyadobacter fermentans enzymes uncovers molecular activity determinants in CE15.
05/14/2024	PubMed	SPINK4 modulates inhibition of glycolysis against colorectal cancer progression.
10/03/2023	News Article	Crickets Market [2023-2031] Size Is Set to Grow At A Remarkable Pace in the Coming Years
09/28/2023	News Article	Serine Market Share, Types, Applications, Products, Size, Growth, Insights and Forecasts Report 2029
09/04/2023	News Article	Security System Integrators Market Size 2023 Booming Worldwide by 2031
01/31/2022	News Article	ChromaDex External Research Program (CERP™) Celebrates 100 Peer-Reviewed Published Studies on Niagen® and Other Ingredients

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

L-serine

Alternative Names: l-serine Clinical Status: Inactive Latest Update: 2025-08-26 Latest Update Note: Clinical Trial Update